The Simparica line of products (manufactured by Zoetis) includes chewable tablets ... and preventing fleas and ticks. Simparica Trio also contains moxidectin and pyrantel.

Zoetis saw notable growth in both companion animal and livestock segments.

Zoetis, Inc. ZTS delivered third-quarter 2024 adjusted earnings (excluding one-time items) of $1.58 per share, which ...

Simparica Trio became the number one vet-prescribed parasiticide, with over 13 million dogs treated, highlighting its market leadership. Zoetis Inc (NYSE:ZTS) successfully divested its medicated ...

Zoetis smashes Q3 estimates, raises full-year guidance, and makes bold moves to dominate animal health innovation ...

Zoetis Inc. (NYSE: ZTS) announced robust financial results for the third quarter of 2024, with revenue reaching $2.4 billion.

3. Parasiticides: Products like Simparica Trio continue to contribute to Zoetis's growth in the companion animal segment. 4. Pipeline Products: Zoetis is developing a promising next-generation ...

Key drivers included high demand for Zoetis’ companion animal products, such as Librela and Solensia, targeting osteoarthritis in pets, and Simparica Trio for flea, tick, and heartworm protection.

Zoetis, Inc. ZTS is expected to beat estimates ... tick and heartworm combination product for dogs, Simparica Trio, are expected to have driven revenues in both the United States and International ...

Simparica Trio became the number one vet-prescribed parasiticide, with over 13 million dogs treated, highlighting its market ...

as well as Zoetis’ parasiticide products, such as Simparica and the Simparica Trio. On a year-over-year basis, livestock product sales increased 7% on a reported basis and 15% operationally to ...

3. Parasiticides: Products like Simparica Trio continue to contribute to Zoetis's growth in the companion animal segment. 4. Pipeline Products: Zoetis is developing a promising next-generation ...